Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Leukemia

Modified Cell Immune Response Key To Defeating Lymphoma, Leukemia

Scientifically-altered T cells, which produce the body’s immune response, may be a key to defeating leukemia, lymphoma, and multiple myeloma, say authors of a new study.

Zenger

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

ISC results: Lucknow girl combats cancer to score 97.75%

LUCKNOW: After 17-year-old Pramita Tewari was diagnosed with Acute Minor Leukemia last year in August, many thought that her future was bleak, but this gritty young girl put up a brave fight. Not only is she on the path of recovery, but also kept her studies going from hospital.

The Times of India

Houston Texans rookie John Metchie III diagnosed with leukemia

John Metchie III, the Houston Texans’ 22-year-old wide receiver, has been diagnosed with leukemia and expects to miss the upcoming season, he announced Sunday.

Tribune News Service

Saban Releases Statement Following Metchie III Leukemia Diagnosis

The Texans rookie receiver starred at Alabama from 2019 to ’21.

Sports Illustrated

Understanding Texans WR John Metchie’s Acute Promyelocytic Leukemia diagnosis

Houston Texans WR John Metchie was diagnosed with Acute Promyelocytic Leukemia, which can be a treatable form of cancer.

USA Today Sports Media Group

Read news from The Economist, FT, and more,
with one subscription

Texans show support for WR John Metchie following Acute Promyelocytic Leukemia diagnosis

Receiver John Metchie drew support from past and present Houston Texans following his announcement of his Acute Promyelocytic Leukemia diagnosis.

USA Today Sports Media Group

Twitter reacts to Leukemia diagnosis of Texans rookie WR John Metchie

Houston Texans rookie receiver John Metchie gathered an outpouring of support on Twitter following his diagnosis of Acute Promyelocytic Leukemia.

USA Today Sports Media Group

Texans rookie WR John Metchie III announces leukemia diagnosis

Houston Texans second-round pick John Metchie III has been diagnosed with acute promyelocytic leukemia

USA Today Sports Media Group

Texans Rookie John Metchie III Announces Leukemia Diagnosis

The Houston wide receiver is expected to miss the 2022 season.

Sports Illustrated

Texans rookie WR John Metchie diagnosed with Acute Promyelocytic Leukemia and likely to miss 2022 season

Houston Texans rookie receiver John Metchie announced his Acute Promyelocytic Leukemia diagnosis, and says he may miss the 2022 season.

USA Today Sports Media Group

John Metchie III diagnosed with Leukemia

Houston Texans rookie wide receiver John Metchie III announced he was diagnosed with a form of Leukemia.

USA Today Sports Media Group

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Belfast Live

Ballymena boy diagnosed with leukemia after limping for weeks

"This has to be any parent's worst nightmare"

Sports Illustrated

Ducks Prospect Finished 2 1/2 Years of Leukemia Treatments

The 22-year-old rang the bell on Monday to officially signal the end of two-and-a-half years of chemo treatments.

Dublin Live

Stephen Bradley shaves his head for young son's charity fundraiser

His son Josh was diagnosed with Acute lymphocytic leukemia last month and the family have started a 'Shave your head' fundraising challenge

Zenger

Deadly Genetics: Gene Mutations May Be Source Of Deadly Blood Cancer

"Identifying a future risk of development of leukemia may ultimately offer the possibility of prevention."

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Precigen Shares Are Gaining Today

Precigen Inc (NASDAQ:PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal consideration includes $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023. …

Benzinga

ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).

Daily Mirror

Boy's large vein turns out to be rare cancer which needs over 2,200 medical procedures

Seb, of Tring, Hertfordshire, was diagnosed with leukemia after a bold vein appeared running from his neck to his groin was actually a sign of cancer

Benzinga

HC Wainwright Believes This Cancer-Focused Stock Is Undervalued At $550M

HC Wainwright initiated coverage of Celularity Inc (NASDAQ:CELU) with a Buy rating and a price target of $15. HC Wainwright believes Celularity's current valuation of approximately $550 million is undervalued considering the upside potential of the company's platform and provides an attractive entry point for long-term investors. The analyst wrote that the company had…

Benzinga

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

Benzinga

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program

LAVA Therapeutics N.V. (NASDAQ:LVTX) hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the American Society of Clinical Oncology and European Hematology Association meetings. "Although preliminary, these data support our view of LAVA-051 as a promising candidate…

Benzinga

Analysts Cuts Price Target On This Small Cap But Remain Bullish

Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ:VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse large B-cell lymphoma and chronic lymphocytic leukemia. It also…

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.